Dificid Approved to Treat C. diff Diarrhea

TUESDAY, May 31 (HealthDay News) -- Dificid (fidaxomicin) has been approved by the U.S. Food and Drug Administration to treat diarrhea associated with Clostridium difficile infection.

Dificid was evaluated in clinical studies involving 564 people with C. diff-associated diarrhea. More people who took Dificid were still symptom-free three weeks after stopping treatment than those who took vancomycin, the FDA said.

Recommended dosage with Dificid is twice daily for 10 days. The most common side effects reported included nausea, vomiting, headache, abdominal pain, and diarrhea.